Onconetix Inc
For the period ended Mar 31, 2024. Filed May 20, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 20, 2024
ONCO$3.58-48.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash | $4,463,870 | $4,554,335 |
| Accounts receivable, net | 252,792 | 149,731 |
| Inventories | 396,312 | 364,052 |
| Prepaid expenses and other current assets | 1,181,723 | 770,153 |
| Total current assets | 6,294,697 | 5,838,271 |
| Prepaid expenses, long-term | 7,792 | 17,423 |
| Property and equipment, net | 56,763 | 60,654 |
| Deferred offering costs | 366,113 | 366,113 |
| Operating right of use asset | 109,360 | 148,542 |
| Intangible assets, net | 21,453,555 | 25,410,887 |
| Goodwill | 46,743,319 | 55,676,142 |
| Total assets | $75,031,599 | $87,518,032 |
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $4,251,394 | $5,295,114 |
| Accrued expenses | 1,936,014 | 2,199,867 |
| Notes payable, net of debt discounts of $198,699 and $381,627 at March 31, 2024 and December 31, 2023, respectively | 10,406,394 | 9,618,373 |
| Note payable – related party, net of debt discount of $225,226 and $0 at March 31, 2024 and December 31, 2023, respectively | 4,774,774 | — |
| Operating lease liability, current | 62,480 | 74,252 |
| Contingent warrant liability | 2,641 | 2,641 |
| Total current liabilities | 21,433,697 | 17,190,247 |
| Note payable | 110,871 | 118,857 |
| Subscription agreement liability – related party | 637,600 | 864,000 |
| Pension benefit obligation | 321,132 | 556,296 |
| Operating lease liability, net of current portion | 46,880 | 74,290 |
| Deferred tax liability, net | 2,743,246 | 3,073,781 |
| Total liabilities | 25,293,426 | 21,877,471 |
| Commitments and Contingencies (see Note 10) | ||
| Series B Convertible Redeemable Preferred stock, $0.00001 par value, 2,700,000 shares authorized at March 31, 2024 and December 31, 2023; 2,696,729 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 64,236,085 | 64,236,085 |
| Stockholders’ equity (deficit) | ||
| Series A Convertible Preferred stock, $0.00001 par value, 10,000 shares authorized at March 31, 2024 and December 31, 2023; 3,000 shares issued and outstanding at March 31, 2024 and December 31, 2023; Liquidation preference of $3,000,000 at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2024 and December 31, 2023; 22,845,100 and 22,841,975 shares issued at March 31, 2024 and December 31, 2023, respectively; 22,327,701 and 22,324,576 shares outstanding at March 31, 2024 and December 31, 2023, respectively | 228 | 228 |
| Additional paid-in-capital | 49,452,674 | 49,428,809 |
| Treasury stock, at cost; 517,399 shares of common stock at March 31, 2024 and December 31, 2023 | (625,791) | (625,791) |
| Accumulated deficit | (67,904,766) | (56,786,194) |
| Accumulated other comprehensive income (loss) | (2,455,546) | 2,380,920 |
| Total Onconetix stockholders’ deficit | (21,533,201) | (5,602,028) |
| Non-controlling interest | 7,035,289 | 7,006,504 |
| Total stockholders’ equity (deficit) | (14,497,912) | 1,404,476 |
| Total liabilities, convertible redeemable preferred stock, and stockholders’ equity (deficit) | $75,031,599 | $87,518,032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.